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BACKGROUND The MARVEL (Micra Atrial TRacking Using a Ventricular AccELerometer) 2 study assessed the efﬁcacy of atrioventricular
(AV) synchronous pacing with a Micra leadless pacemaker. Average
atrioventricular synchrony (AVS) was 89.2%. Previously, low amplitude of the Micra-sensed atrial signal (A4) was observed to be a factor of low AVS.
OBJECTIVE The purpose of this study was to identify predictors of
A4 amplitude and high AVS.
METHODS We analyzed 64 patients enrolled in MARVEL 2 who had
visible P waves on electrocardiogram for assessing A4 amplitude and
40 patients with third-degree AV block for assessing AVS at rest.
High AVS was deﬁned as .90% correct atrial-triggered ventricular

pacing. The association between clinical factors and echocardiographic parameters with A4 amplitude was investigated using a
multivariable model with lasso variable selection. Variables associated with A4 amplitude together with premature ventricular
contraction burden, sinus rate, and sinus rate variability (standard
deviation of successive differences of P-P intervals [SDSD]) were assessed for association with AVS.
RESULTS In univariate analysis, low A4 amplitude was inversely
related to atrial function assessed by E/A ratio and eʹ/aʹ ratio,
and was directly related to atrial contraction excursion (ACE) and
atrial strain (Ɛa) on echocardiography (all P .05). The multivariable lasso regression model found coronary artery bypass graft history, E/A ratio, ACE, and Ɛa were associated with low A4 amplitude.
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E/A ratio and SDSD were multivariable predictors of high AVS, with
.90% probability if E/A ,0.94 and SDSD ,5 bpm.

KEYWORDS Atrioventricular block; Atrioventricular synchrony;
Leadless pacing; Micra transcatheter pacemaker; Predictors

CONCLUSION Clinical parameters and echocardiographic markers
of atrial function are associated with A4 signal amplitude. High
AVS can be predicted by E/A ratio ,0.94 and low sinus rate variability at rest.

(Heart Rhythm 2020;17:2037–2045) © 2020 The Heart Rhythm
Society. Published by Elsevier Inc. on behalf of Heart Rhythm
Society. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Background

2 study was to conﬁrm the ability of an enhanced downloaded
algorithm (MARVEL 2 algorithm) to provide AV synchronous pacing by mechanically sensing atrial contraction via
the accelerometer signal from a ventricular Micra leadless
pacemaker. The primary efﬁcacy objective was to demonstrate the superiority of the MARVEL 2 algorithm to provide
AV synchronous pacing relative to VVI pacing in subjects
with persistent third-degree AV block and NSR at rest.
The protocol was approved by all local ethics committees
and national regulatory agencies at each participating institution. All patients provided written informed consent.

In patients with normal sinus rhythm (NSR) and high-degree
atrioventricular (AV) block, AV synchronous pacing mode
improves stroke volume, cardiac output, and quality of life,
and reduces the incidence of pacemaker syndrome and atrial
ﬁbrillation (AF). However, it does not reduce mortality or
occurrence of stroke.1–3 Therefore, pacing modes that
preserve
atrioventricular
synchrony
(AVS)
are
recommended as a class I indication in patients who have
high-degree AV block and NSR requiring permanent pacing,
with dual-chamber pacemakers as the ﬁrst choice and singlelead VDD pacing systems as an alternative.4 Leadless pacemakers were designed to reduce complications associated
with transvenous pacemakers, particularly lead- and
pocket-related complications, which historically have been
reported to range as high as 2%–12%.5,6 Leadless pacemakers have demonstrated a high safety and efﬁcacy proﬁle.7
However, ﬁrst-generation leadless pacemakers deliver only
ventricular pacing (VVI[R] mode), which largely limits their
use to patients with bradycardia and chronic AF and those
considered to be at high risk for complications related to implantation of a leaded pacemaker. Recently, secondgeneration leadless pacemakers have expanded pacing
modes to include AV synchronous pacing.
The MARVEL (Micra Atrial TRacking Using a Ventricular AccELerometer) 1 and 2 studies demonstrated the feasibility of delivering AV synchronous pacing using a
ventricular Micra leadless pacemaker (Medtronic, Inc, Minneapolis, MN, US).8,9 Speciﬁcally, the MARVEL 2 algorithm
demonstrated a generally high proportion of AVS in patients
with AV block, showing .95% of patients had .70% AVS at
rest and increased left ventricular stroke volume. Notably, the
optimal percentage of AVS required to maintain beneﬁt while
minimizing pacemaker syndrome has not been determined.
Two key factors inﬂuence high AVS with mechanical
sensing–based VDD pacing: preoperative patient selection
and postoperative management. Patient selection may be
the more important of these 2 factors. The amplitude of the
sensed mechanical atrial signal (A4) by the Micra accelerometer cannot be assessed before the implant procedure but is
fundamental to ensure a high AVS percentage. Therefore,
we sought to identify clinical predictors of A4 signal amplitude and determinants of a high AVS percentage.

Methods
Study design
The MARVEL 2 study was a prospective, nonrandomized
multicenter clinical trial.9 The primary aim of the MARVEL

Patients and procedures
All patients who were enrolled in the MARVEL 2 study and
received the MARVEL 2 algorithm download were eligible
for inclusion in this analysis. These patients were aged
.18 years, had a history of AV block, and had previously undergone or were undergoing implant with a Micra.
The MARVEL 2 study procedures and algorithm
(Supplemental Figure S1) have been previously described.9
In brief, custom software was temporarily downloaded into
the Micra. A specialized Holter monitor was placed during
study procedures to collect the electrocardiogram (ECG),
electrogram (EGM), accelerometer waveform, and device
markers. Performance was characterized with the patient at
rest in a supine or sitting position (approximately 20 minutes).

Echocardiographic analysis
Echocardiograms were collected during VVI at a lower rate
of 50 bpm. An echocardiography core laboratory (United
Heart and Vascular, St. Paul, MN) measured parameters
related to cardiac function in 2-, 3-, 4-, and 5-chamber and
parasternal short-axis views. The laboratory was blinded to
patient and study center. Previous studies have shown that
atrial contraction can be seen in the right ventricular (RV)
tricuspid annular plane systolic excursion view.10,11 To characterize atrial function in this view, we deﬁned a parameter—
atrial contraction excursion (ACE)—as the displacement during atrial contraction (Supplemental Figure S2).

ECG analysis
P waves were identiﬁed on surface ECG/Holter monitor by a
technician blinded to the device and algorithm markers. An
individual cardiac cycle was considered synchronous if a
paced or sensed ventricular event occurred within 300 ms
following a P wave. Sinus rate variability was calculated
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by the standard deviation of successive differences of
P-P intervals (SDSD) method.12
In a subset of patients (n 5 19) at 1 center (University
Hospitals of Leuven, Leuven, Belgium), high-ﬁdelity measurements of P-wave amplitude and duration were made
from a 12-lead ECG using the MUSE Cardiology Information System (GE Medical Systems, Menomonee Falls, WI).
These measurements were made by 2 observers who were
blinded to AVS.

Statistical analysis
All patients with visible P waves on surface ECG were
included in the analysis of A4 amplitude (n 5 64), whereas
only those with a predominant rhythm of persistent thirddegree AV block and NSR (n 5 40) were included in the
analysis of AVS percentage, as patients with intact AV conduction would have high AVS regardless of A4 sensing.
Based on previous reports using conventional VDD pacing
systems, we deﬁned high/satisfactory AVS as .90%.13–16
Demographics, medical history, and other baseline
variables were compared among patients with .90% and
90% AVS using the Wilcoxon rank-sum test for continuous
variables and the Fisher exact test for continuous variables.
A4 amplitude was compared among patients with .90%
and 90% AVS using the Student t test.
A 2-step modelling process was used to identify predictors
of high AVS percentage (Supplemental Figure S3). First, to
utilize the largest number of patients we identiﬁed predictors
of A4 amplitude. Next we included any multivariable predictors of A4 amplitude together with measures of sinus rate, sinus rate variability, and premature ventricular complex
(PVC) burden to identify predictors of high AVS.
Baseline medical history (n 5 16 variables), cardiovascular medication use (n 5 7 variables), echocardiographic measures (n 5 26 variables), months since Micra implant, and
device location in the RV were tested for univariate association with A4 amplitude using ordinary linear regression
(Supplemental Table S1). After univariate regression, 9 echocardiographic variables were dropped from multivariable
consideration because they were constructs of more clinically
relevant variables (eg, left atrial ejection fraction was
included, whereas left atrial end-diastolic volume and left
atrial end-systolic volume were excluded). Due to the presence of missing data (primarily in echocardiographic parameters), 100 imputed datasets with complete data were created
using multivariate imputation by chained equations (MICE).
Due to the large number of candidate prognostic variables
(n 5 42) relative to the total sample size, lasso regression
was used to identify multivariable predictors of A4 amplitude
in each of the 100 imputed datasets. Lasso is a regression
technique that selects variables maximizing prediction accuracy while penalizing overﬁtting rather than performing variable selection based on traditional measures of statistical
signiﬁcance. Candidate variables selected by lasso in at least
50% of imputed datasets were incorporated in the ﬁnal
model. The ﬁnal model for A4 amplitude was ﬁt to each of
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the imputed datasets using linear regression, with the results
pooled across the repeated analyses using Rubin’s rules to account for the added variability due to the missing data.
In addition, the association between the absolute value of
P-wave amplitude and P-wave duration with A4 amplitude
was quantiﬁed using the Pearson correlation coefﬁcient.
Variables included in the ﬁnal A4 amplitude model
together with sinus rate, sinus rate variability (SDSD), and
PVC burden were assessed for their univariate association
with high AVS using univariate logistic regression. As
none of these variables had missing values, multivariable
analysis was performed on the original dataset. Multivariable
predictors of high AVS were determined using lasso logistic
regression, with the ﬁnal model ﬁt using ordinary logistic
regression. In-sample discrimination ability of the ﬁnal
model was assessed by determining the area under the
receiver operating characteristic curve (AUROC).
Analysis was conducted in SAS Version 9.4 (SAS Institute,
Cary, NC) and R (R Core Team, 2017), utilizing the mice,17
glmnet,18 and ROCR19 packages to implement MICE, lasso
variable selection, and ROC analyses, respectively.

Results
Baseline characteristics
Overall, 75 patients were enrolled in the MARVEL 2 study
and received the software download. Mean age was 77.5 6
11.8 years (range 21–94 years), and 30 patients (40%) were
female (Table 1). Among the 75 patients, 40 (53%) had
persistent third-degree AV block with NSR, 18 (24%) had
1:1 AV conduction, 6 (8%) had varying AV conduction
and NSR, and 11 (15%) did not have visible P waves on
ECG due to either AF or ﬂutter (n 5 8) or noise on the
ECG (n 5 3). The 11 patients with no visible P waves on
ECG were excluded from the analysis of A4 amplitude
because the lack of P waves prevented association of A4 signals with conﬁrmed atrial activity. Patient characteristics by
analysis cohort are listed in Table 1.
Median AVS in the 40 patients with persistent third-degree
AV block and NSR was 94.3% (interquartile range [IQR]
81.1%–97.4%). Of these patients, 25 (62.5%) had AVS
.90% (median AVS 96.9%; IQR 95.3%–98.1%); the remaining 15 patients had AVS 90% (median AVS 79.6%; IQR
77.3%–81.6%). Among the patients with AVS .90%, mean
A4 amplitude was higher than in patients with AVS 90%
(3.1 6 1.2 m/s2 vs 2.4 6 0.8 m/s2; P 5 .030) (Figure 1). Overall, mean A4 amplitude was 2.8 6 1.1 m/s2.

Factors associated with A4 amplitude
Of the 51 candidate predictor variables, 18 had a univariate association with A4 amplitude at the P ,.1 level (Table 2 and
Supplemental Table S1). Variables related to atrial function
were associated with A4 amplitude, such as E/A ratio, ACE,
eʹ/aʹ ratio, and atrial strain (all P .05). There was no signiﬁcant association between device location and A4 amplitude. In
addition, age, body mass index, and RV ejection fraction were
not associated with A4 amplitude. There was no difference in
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Baseline patient characteristics

Characteristics
Age (y)
Mean 6 SD
Median (IQR)
BMI
Mean 6 SD
Median (IQR)
Female
LV ejection fraction (%)
Mean 6 SD
Median (IQR)
RV ejection fraction (%)
Mean 6 SD
Median (IQR)
LA end-diastolic volume (mL)
Mean 6 SD
Median (IQR)
Comorbidities [n (%)]
Hypertension
Atrial ﬁbrillation
Diabetes
Coronary artery disease
CABG
Valve surgery
COPD
Dialysis
Device location [n (%)]
RVOT
RV high-septum
RV mid-septum
RV low-septum
RV apex
Other
Predominant rhythm [n (%)]
Complete AV block with NSR
Intact AV conduction
Other rhythm
Indeterminate rhythm

All patients
(N 5 75)

Analysis of A4
amplitude (n 5 64)

AVB 1 NSF AVS .90%
(n 5 25)

AVB 1 NSF AVS 90%
(n 5 15)

77.5 6 11.8
81.0 (72.0–85.0)

77.0 6 12.4
80.0 (71.5–84.0)

78.8 6 10.2
80.0 (75.0–84.0)

73.0 6 16.3
77.0 (67.0–84.0)

26.2 6 5.7
25.4 (22.6–28.0)
30 (40.0%)

26.8 6 6.0
25.6 (23.4–28.4)
29 (45.3%)

25.9 6 3.4
26.1 (23.2–28.4)
16 (64.0%)

29.3 6 9.2
25.3 (23.6–33.1)
6 (40.0%)

53.5 6 3.8
54.0 (52.0–56.0)

53.8 6 3.9
55.0 (52.0–56.0)

54.3 6 3.4
55.0 (53.0–56.0)

53.5 6 3.3
53.5 (51.0–56.0)

43.0 6 8.2
42.9 (37.3–47.5)

43.0 6 8.4
43.0 (36.8–48.2)

43.3 6 9.7
42.9 (36.5–51.8)

41.5 6 9.2
42.1 (34.5–47.5)

54.9 6 19.4
56.0 (39.0–68.0)

52.3 6 18.6
53.0 (35.0–65.0)

46.1 6 12.0
43.0 (36.0–58.0)

58.7 6 23.0
65.0 (29.0–80.0)

2 (69.3)
14 (18.7)
13 (17.3)
23 (30.7)
9 (12.0)
18 (24.0)
7 (9.3)
3 (4.0)

4 (70.3)
7 (10.9)
13 (20.3)
20 (31.3)
8 (12.)
14 (21.9)
(7.8)
3 (4.7)

17 (68.0)
0 (0.0)
3 (12.0)
(20.0)
3 (12.0)
(20.0)
2 (8.0)
1 (4.0)

11 (73.3)
3 (20.0)
3 (20.0)
3 (20.0)
1 (6.7)
2 (13.3)
2 (13.3)
0 (0.0)

12 (16.0)
11 (14.7)
26 (34.7)
12 (16.0)
12 (16.0)
2 (2.7)

11 (17.2)
10 (1.6)
21 (32.8)
10 (1.6)
10 (1.6)
2 (3.1)

1 (4.0)
6 (24.0)
7 (28.0)
(20.0)
6 (24.0)
0 (0.0)

3 (20.0)
1 (6.7)
4 (26.7)
3 (20.0)
2 (13.3)
2 (13.3)

40 (3.3)
18 (24.0)
1 (20.0)
2 (2.7)

40 (62.)
17 (26.6)
7 (10.9)
0 (0.0)

2 (100.0)
0 (0.0)
0 (0.0)
0 (0.0)

1 (100.0)
0 (0.0)
0 (0.0)
0 (0.0)

P value*
.26
.72
.19
.38
.62
.12

1
.046
1
1
1
.69
1
1
.20

N/A

AV 5 atrioventricular; AVB 5 high-degree atrioventricular block; AVS 5 atrioventricular synchrony; BMI 5 body mass index; CABG 5 coronary artery bypass
graft; COPD 5 chronic obstructive pulmonary disease; IQR 5 interquartile range; LA 5 left atrium; LV 5 left ventricle; NSF 5 normal sinus function; RV 5 right
ventricle; RVOT 5 right ventricular outﬂow tract.
*P value for comparison between AVB 1 NSR patients with .90% AV synchrony vs AVB 1 NSR with 90% synchrony based on Wilcoxon rank-sum test for continuous variables and Fisher exact test for categorical variables.

A4 amplitude among patients with third-degree AV block and
NSR vs patients with intrinsic conduction.
The lasso regression model selected coronary artery
bypass graft history, E/A ratio, ACE, and atrial strain for their
multivariable association with A4 amplitude (Table 2). The
ﬁnal model for A4 amplitude accounted for 37.9% of the
variability in the observed A4 amplitude.
In the subset of patients with high-ﬁdelity measurements of
P-wave amplitude and duration, the strongest association with
A4 amplitude was P-wave amplitude in lead aVR (r 5 0.52;
P 5 .023). There was no association between A4 amplitude
and P-wave duration (r 5 0.13; P 5 .61).

Factors associated with AVS
The 4 multivariable predictors of A4 amplitude, plus average
sinus rate, sinus rate variability (SDSD ,5 bpm vs SDSD

5 bpm), and PVC burden (,2% vs 2%), were tested for
their univariate and multivariable relationship with high
AVS (Table 3).
None of the 40 patients with persistent third-degree AV
block and NSR were missing data from the 7 candidate predictors. The lasso procedure identiﬁed SDSD and E/A ratio
as multivariable predictors of high AVS. E/A ratio was negatively associated with high AVS (odds ratio 0.4 per 0.23-unit
increase; 95% conﬁdence interval [CI] 0.16–1.01; P 5 .051),
and SDSD ,5 bpm was positively associated with high AVS
(odds ratio 16.6; 95% CI 2.4–112.5; P 5 .004). The ﬁnal
model for high AVS discriminated well with AUROC of
0.89 (95% CI 0.75–0.98). The model predicts a .90% probability of high AVS if E/A ,0.94 and SDSD ,5 bpm and a
,10% probability of high AVS if either (1) E/A .2.0 and
SDSD ,5 bpm or (2) E/A .1.3 and SDSD 5 bpm
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Figure 1 A4 amplitude vs high atrioventricular (AV) synchrony status during rest in patients with persistent third-degree AV block and normal sinus rhythm
(n 5 40). Horizontal black lines on boxes are median values. Height of boxes corresponds to interquartile range. Points represent individual patient values.

(Figure 2A). The relationship between E/A ratio, SDSD, and
AVS percentage is shown in Figure 2B.

Discussion
The present study evaluated both the predictors of the A4
signal amplitude mechanically detected by the accelerometer
contained in the Micra leadless pacemaker and the determinants of high AVS during VDD mode. Our ﬁndings based
on the MARVEL 2 population provide insight into the selection of patients who could beneﬁt from a leadless device that
promotes AVS.

Quality of the A4 signal
Although it is possible to track a low-amplitude A4 signal
with the MARVEL 2 algorithm, patients who exhibited
high AVS (.90%) had a mean A4 signal amplitude higher
than that of patients with a lower AVS (90%) (Figure 1).
In multivariable analysis, the amplitude of the A4 signal
correlated with the echocardiographic parameters E/A ratio,
ACE, and atrial strain. ACE and atrial strain both are markers
of atrial contraction strength.
Of interest, patient characteristics including age, body mass
index, arterial blood pressure, and history of previous atrial
arrhythmia were not multivariable predictors of A4 amplitude.
Curiously, coronary artery bypass graft had a negative relationship with A4 amplitude. The reduction in A4 amplitude
may be related to severity of ischemic disease20 and to right
atrial cannulation during cardiopulmonary bypass surgery,

both factors potentially leading to a reduction in atrial contraction. Device position was not associated with A4 amplitude.
Therefore, no changes to the implant procedure of the Micra
are currently recommended to optimize A4 sensing.
In our study, a low A4 amplitude was associated with low
ACE and atrial strain, which are parameters of atrial function.
Whether AV synchronous pacing would be beneﬁcial in patients with impaired atrial function is not clear. An increased
risk of stroke has been observed after the maze procedure in
patients in sinus rhythm with a low P-wave amplitude and
absence of left atrial mechanical activity.21 The lack of atrial
contractile activity may explain the absence of reported
beneﬁt of DDD vs VVI pacing on mortality in patients
with NSR and high-degree AV block.1,2,22 Impairment of
atrial mechanical function over time also can lead to atrial
undersensing. Its clinical signiﬁcance will need to be evaluated in future clinical studies. Nevertheless, Marchandise
et al23 previously showed that atrial undersensing had no
clinical impact in patients with high-degree AV block treated
by a conventional VDD system.
In a small group of patients (n 5 19), A4 signal amplitude
was correlated with the amplitude of the initial deﬂection of
the P wave measured in aVR derivation on 12-lead ECG. To
our knowledge, there is no clear evidence of a relationship between P-wave morphology and right atrial mechanical activity
in healthy atria. Nevertheless, a low P-wave amplitude (0.05
mV) in the septal anterior leads has been associated with
absence of left atrial mechanical contraction after modiﬁed
Maze procedures.21
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Univariate and multivariable predictors of A4 amplitude during rest
Univariate models

Multivariable model

Variable
type

Variable

Subjects

Summary*

b (95% CI)

Baseline
medical history

Male
Systolic blood pressure

64
63

–0.57 (–1.25 to 0.10)
0.02 (0.00 to 0.04)

.099
.036

0.04
0.07

Echocardiography

History of atrial arrhythmias
Previous CABG
Previous valve surgery
Four-chamber TR jet area

64
64
64
60

–0.81 (–1.73 to 0.11)
–1.41 (–2.38 to –0.44)
–0.80 (–1.60 to 0.00)
–0.15 (–0.32 to 0.01)

.089
.006
.056
.077

0.05
0.12
0.06
0.05

LV ejection fraction

62

0.21 (0.02 to 0.39)

.030

0.08

LA end-diastolic volume

63

–0.12 (–0.25 to 0.02)

.088

0.05

LA end-systolic volume

63

–0.13 (–0.25 to 0.00)

.055

0.06

LA ejection fraction

63

0.13 (–0.01 to 0.28)

.070

0.05

E/A (mitral valve)

63

–0.25 (–0.39 to –0.10)

.002

0.15

RV TAPSE

64

0.23 (0.10 to 0.37)

.001

0.15

ACE

64

0.34 (0.18 to 0.49)

,.001

0.23

E/eʹ

62

–0.12 (–0.27 to 0.02)

.097

0.05

e/aʹ lateral

62

–0.19 (–0.34 to –0.03)

.024

0.08

eʹ/aʹ septal

62

–0.16 (–0.31 to –0.01)

.039

0.07

eʹ/aʹ average

62

–0.24 (–0.41 to –0.08)

.005

0.12

Atrial strain (Ɛa)

64

54.7%
137 6 20
136
119–152
92–176
15.6%
12.5%
21.9%
362
2
1–4
012
54 6 4
55
52–56
40–61
52 6 19
53
35–65
19–92
25 6 10
25
16–30
8–44
53.2 6 4.0
53.3
50.0–55.9
46.2–63.0
1.18 6 0.62
0.93
0.79–1.26
0.48–3.43
2.4 6 0.5
2.4
0.9–1.1
1.4–3.4
1.0 6 0.2
1.0
0.9–1.1
0.5–1.7
12.67 6 6.27
10.62
7.96–15.77
4.10–31.41
1.25 6 0.85
1.00
0.75–1.38
0.47–4.57
1.27 6 1.01
0.87
0.71–1.37
0.45–5.00
1.18 6 0.66
0.96
0.77–1.22
0.54–3.90
8.3 6 4.4
7.7
4.6–10.7
1.2–21.6

0.16 (0.01 to 0.32)

.045

0.06

†

P value

2

R

b (95% CI)†

P value

–1.01 (–1.88 to –0.13)

.025

–0.13 (–0.28 to 0.02)

.092

0.26 (0.11 to 0.42)

.001

0.11 (–0.03 to 0.24)

.117

ACE 5 atrial contraction excursion; CABG 5 coronary artery bypass graft; CI 5 conﬁdence interval; LA 5 left atrium; LV 5 left ventricle; RV 5 right ventricle;
TAPSE 5 tricuspid annular plane systolic excursion; TR 5 tricuspid regurgitation.
*Summary values are given as mean 6 SD, median, interquartile range, and range for continuous variables or percentage for categorical variables.
†
Regression b values are standardized for continuous variables to represent an increase in 10% of the observed range.
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Univariate and multivariable predictors of AVS during rest
Univariate models

Multivariable model

Variable

Subjects

Summary*

Odds ratio (95% CI)†

P value

Previous CABG
SDSD ,5 bpm
PVC burden ,2%
Average P-P interval (bpm)

40
40
40
40

1.9 (0.2–20.2)
14.4 (3.0–69.1)
0.8 (0.1–9.9)
1.0 (0.8–1.3)

.591
,.001
.877
.987

E/A (mitral valve)

40

ACE

40

Atrial strain (Ɛa)

40

10.0%
62.5%
92.5%
73.3 6 11.1
71.8
65.6–82.3
51.9–96.6
1.12 6 0.51
0.93
0.80–1.19
0.65–2.97
1.0 6 0.2
1.0
0.9–1.2
0.6–1.6
7.9 6 3.5
7.9
4.6–10.5
1.2–16.3

0.5 (0.3–0.9)

.021

1.2 (0.9–1.6)

.311

1.2 (0.9–1.6)

.232

Odds ratio (95% CI)†

P value

16.6 (2.4–112.6)

.004

0.4 (0.16–1.01)

.051

PVC 5 premature ventricular complex; SDSD 5 standard deviation of successive P-P interval difference; other abbreviations as in Tables 1 and 2.
*Summary values are given as mean 6 SD, median, interquartile range, and range for continuous variables or percentage for categorical variables.
†
Odd ratios are standardized for continuous variables to represent an increase in 10% of the observed range.

High AVS
No preimplant measurement of A4 signal amplitude is available to identify patients who may have high (or low) AVS.
Based on ECG and echocardiographic parameters, we
showed that low sinus rate variability (SDSD ,5 bpm) combined with E/A ratio ,0.94 predicts high AVS (.90%) with
.90% probability. Furthermore, high sinus rate variability
and/or high E/A ratio can select patients unlikely to achieve
high AVS most of the time. Patient age and average sinus
rate had no inﬂuence on AVS.
Leadless pacemakers with a VDD pacing mode based on
mechanical atrial sensing are intended to treat patients with
high-degree AV block and NSR. Previously the cumulative
incidence of sinus node dysfunction at 5 years was shown
to be 2.6% in patients with no history of sinus dysfunction
and 4.6% in patients having a preimplant sinus rate .70
bpm when treated with single-lead VDD pacing.24 Therefore,
depending on a patient’s risk proﬁle and the potential advantage of the leadless pacing technology, dual-chamber pacing
systems should be preferred in the presence of sinus node
dysfunction and high-degree AV block.

variability of echocardiographic measurements among individual laboratories may be less consistent. Also, sinus variability is not frequently assessed, especially in patients with
third-degree AV block, and quantiﬁcation of P-P intervals
in a clinical setting may be impractical. Therefore, the proposed predictors for A4 amplitude and high AVS over time
should be validated in a larger population with longer
follow-up.

Conclusion
The amplitude of the sensed mechanical atrial signal (A4) by
the Micra accelerometer was related to atrial function assessed by echocardiography. We were able to predict, with
high probability, high AVS .90% in the presence of E/A ratio ,0.94 and low sinus rate variability at rest (assessed by
SDSD). These ﬁndings, if appropriately validated in a future
patient population, may be used to improve the selection of
patients for leadless VDD pacing systems.
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Figure 2 Atrioventricular synchrony (AVS) percentage by E/A ratio and sinus rate variability as measured by standard deviation of the successive differences of
P-P intervals (SDSD) method. A: Model predicted probability AVS is .90% by E/A ratio and SDSD status. Dashed black lines indicate E/A ratio required for .10%
and .90% chance of exceeding 90% AV synchrony. B: AVS percentage vs E/A ratio at screening by SDSD status. Red dashed line indicates 90% AVS.
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